BioSpace News Archive

Simulations Plus, Inc. announced that its Lixoft division, a leading provider of population PKPD modeling solutions for pharmacometricians and biostatisticians, has released an update to version 2021R1 of its MonolixSuite platform.

InterVenn Biosciences to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022.

Dermata Therapeutics, Inc. announced that Gerry Proehl, Dermata’s Chairman of the Board, President, and Chief Executive Officer, will present a company overview at the H.C. Wainwright BioConnect Virtual Conference being held January 10-13, 2022.

Invectys Inc. a clinical-stage immunotherapy company headquartered in Houston and dedicated to the development of a new generation of products for cancer patients, today announced that Praveen Tyle, Ph.D., Invectys Inc. President and CEO will participate in the JP Morgan Healthcare Meeting held virtually on January 10-13, 2022.

Australia- and New York-based Smileyscope Holding Inc (Smileyscope™) announced today the US Patent and Trade Office has awarded a patent for its innovative approach to synchronizing procedures with Virtual Reality/Augmented Reality (VR/AR) stimuli.

Silverback Therapeutics, Inc. announced that Silverback management will participate in the H.C. Wainwright Bioconnect Conference from January 10-13, 2022.

Suono Bio, Inc., the company revolutionizing the treatment of gastrointestinal diseases, today announced its latest publication in the Journal of Pharmaceutical Sciences demonstrating the capability to deliver unformulated RNA therapeutics against relevant disease targets in the gastrointestinal tract.

Viewpoint Molecular Targeting, Inc. announced that Frances L. Johnson MD, Chief Executive Officer and Co-Founder of Viewpoint, will present at the virtual H.C. Wainwright BioConnect Conference taking place January 10-13, 2022.

MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S. Patent and Trademark Office (USPTO) awarded to the company U.S. Patent 11,219,620 B2, titled “Method of Treating Sarcopenia.”

An important public health webinar focused on the Bartonella species, the bacterium that causes Bartonellosis, is now available on demand at https://education.quidel.com/educational-categories.